If a >50% reduction in LDL is achieved but LDL remains above 100 in patients with no history of clinically significant atherosclerosis, or above 70 in patients with a history of atherosclerosis, it is recommended to add ezetimibe if <25% additional LDL lowering is required, or a proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody if >25% LDL reduction is needed (30). The gene discussed is PCSK9; the disease is atherosclerosis.